Applied pharmacogenomics in cardiovascular medicine.

Weeke P, Roden DM
Annu Rev Med. 2014 65: 81-94

PMID: 24111889 · PMCID: PMC4081861 · DOI:10.1146/annurev-med-101712-122545

Interindividual heterogeneity in drug response is a central feature of all drug therapies. Studies in individual patients, families, and populations over the past several decades have identified variants in genes encoding drug elimination or drug target pathways that in some cases contribute substantially to variable efficacy and toxicity. Important associations of pharmacogenomics in cardiovascular medicine include clopidogrel and risk for in-stent thrombosis, steady-state warfarin dose, myotoxicity with simvastatin, and certain drug-induced arrhythmias. This review describes methods used to accumulate and validate these findings and points to approaches--now being put in place at some centers--to implementing them in clinical care.

MeSH Terms (18)

Adrenergic beta-Antagonists Antihypertensive Agents Antithrombins Aryl Hydrocarbon Hydroxylases Cardiovascular Diseases Clopidogrel Cytochrome P-450 CYP2C9 Cytochrome P-450 CYP2C19 Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors Liver-Specific Organic Anion Transporter 1 Organic Anion Transporters Pharmacogenetics Polymorphism, Single Nucleotide Precision Medicine Ticlopidine Vitamin K Epoxide Reductases Warfarin

Connections (1)

This publication is referenced by other Labnodes entities: